Table 3.

The HR for OS and PFS of NLR was pooled in subgroup analyses.

Subgroup	PFS				OS
	Study	HR [95%CI]	P value	I2	Study	HR [95%CI]	P value	I2
Country
China	8	1.75 (1.46,2.11)	P<0.001	7.2	9	2.08 (1.71,2.55)	P<0.001	7.8
Japan	4	1.28 (1.00,1.65)	0.049	0	4	1.90 (1.41,2.54)	P<0.001	0
South Korea	1	2.17 (1.04,4.51)	0.038	NA	2	1.84 (1.16,2.93)	0.009	0
Sample size
<100	10	1.53 (1.30,1.79)	P<0.001	17.2	10	2.04 (1.69,2.47)	P<0.001	0
≥100	3	1.96 (1.37,2.8)	P<0.001	0	5	1.91 (1.45,2.52)	P<0.001	0
cut-off
≥3	6	1.66 (1.33,2.07)	P<0.001	0	6	2.06 (1.65,2.57)	P<0.001	0
<3	6	1.69 (1.37,2.10)	P<0.001	17	6	2.22 (1.69,2.92)	P<0.001	29.5
Study design
Retrospective	11	1.51 (1.29,1.77)	P<0.001	2.9	11	1.90 (1.61,2.25)	P<0.001	0
Prospective	2	2.16 (1.46,3.17)	P<0.001	0	2	2.82 (1.84,4.32)	P<0.001	56.4
Follow-up
≤15	6	1.62 (1.33,197)	P<0.001	33.1	5	2.25 (1.77,2.85)	P<0.001	19.7
>15	7	1.55 (1.25,1.93)	P<0.001	0	10	1.83 (1.49,2.25)	P<0.001	0
Combined medication
Monotherapy	8	1.52 (1.28,1.81)	P<0.001	21.1	9	1.95 (1.59,2.39)	P<0.001	19.7
Combined therapy	5	1.76 (1.35,2.31)	P<0.001	0	6	2.08 (1.63,2.65)	P<0.001	0

NA, Not Applicable.